Working well can still mean due to stop, in an NU553 Unit 5 reflection where one author's case for continuing alendronate meets the task force evidence that overturned it. Searches like "nu 553 unit 5 assignment example", "nu553 unit 5 sample" and "nu553 unit 5 example" land here.
I Argued to Continue: A Reflection on Losing a Seminar Debate About a Drug Holiday From Alendronate
[Student Name]
Purdue University Global
NU553: Advanced Pharmacology and Pharmacotherapeutics
Unit 5 Seminar Reflection
[Instructor Name]
[Date]
The patient is a composite used in the seminar; no real patient is described.
Where I Started
I came into the seminar sure of my position. Mrs. [E.], 72, had taken alendronate weekly for five years without a fracture. Her femoral neck T-score was -2.1, better than the -2.6 at which she started, but still close to the osteoporosis line. My reasoning was simple: the drug was working, she had no side effects, and stopping it would risk giving back what five years had built. I was afraid of being the clinician who stopped a drug and then saw a hip fracture.
The case for continuing deserves to be stated fairly, because it is not foolish. Her bone density had risen only modestly, and she remained in the osteopenic range. At 72, her fracture risk would rise with every year of age regardless of treatment. And no one wants to explain to a patient why a medicine that was helping was stopped.
What the Evidence Said
The session did not change my mind because the room disagreed with me. It changed my mind because two documents did, and I will record the discussion by source rather than by speaker.
The ASBMR task force report. A classmate who had read the 2016 ASBMR task force report on long-term bisphosphonate use walked us through its algorithm. For women who have taken an oral bisphosphonate for five years, the report suggests considering a drug holiday of two to three years if the femoral neck T-score is above -2.5 and there is no history of hip, spine or multiple other osteoporotic fractures (Adler et al., 2016). Women who remain at high risk, those with a T-score at or below -2.5 or a prior fracture, should generally continue. Mrs. [E.], at -2.1 with no fracture, fell on the side of the line where a holiday is suggested.
The FLEX trial. Another classmate described the Fracture Intervention Trial Long-term Extension, in which women who had taken alendronate for about five years were randomized to continue for five more or to switch to placebo (Black et al., 2006). Continuing reduced clinical vertebral fractures, but it did not reduce nonvertebral fractures, including hip fractures, and bone density in the placebo group fell only gradually. The reason is pharmacological. Alendronate binds to bone mineral and is released slowly over years, so its effect persists after the tablets stop. A drug holiday from alendronate is not the same as stopping a drug that leaves the body in hours; the skeleton keeps a reservoir.
The Harms That Grow With Time
The third part of the discussion was about harms, and I was glad our facilitator kept it measured. Two rare complications become more likely with longer bisphosphonate use. Atypical femoral fractures, breaks in the shaft of the femur after little or no trauma, rise with duration of use and fall quickly after the drug is stopped. In a large cohort of women, the number of hip and other fragility fractures prevented far exceeded the number of atypical fractures caused, but the balance narrowed with longer use (Black et al., 2020). Osteonecrosis of the jaw is very rare at the doses used for osteoporosis.
Neither harm is common enough to frighten a patient out of treatment she needs. Their relevance here is narrower. After five years, the added benefit of continuing is smaller for a woman at moderate risk, while these harms continue to accumulate. That changes the balance, not the verdict on the drug.
My Revised View
I now think a drug holiday is reasonable for Mrs. [E.], under conditions. The pause is not an ending. Her bone density would be checked at two years, and the holiday would end early if she had a new fracture, a significant fall in bone density or a new risk factor, such as starting long-term glucocorticoids. If her T-score falls to -2.5 or below, treatment resumes.
My fear of being blamed for a fracture was real, and I think it is a common reason clinicians continue treatment beyond the point where evidence supports it. What I learned is that the evidence gives a way to decide, not only a way to avoid blame.
What Remained Unsettled
One question the session did not resolve was how to handle a woman in the middle, with a T-score of, say, -2.4 and a strong family history of hip fracture. The task force report allows judgment in such cases, and our group split on how to exercise it. I left thinking that the right answer depends as much on how the patient weighs a small risk of a rare harm against a small reduction in a common one, and that asking her is part of the pharmacology.
References
Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., Greenspan, S. L., McKinney, R., Pignolo, R. J., & Sellmeyer, D. E. (2016). Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 31(1), 16-35. https://doi.org/10.1002/jbmr.2708
Black, D. M., Geiger, E. J., Eastell, R., Vittinghoff, E., Li, B. H., Ryan, D. S., Dell, R. M., & Adams, A. L. (2020). Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. New England Journal of Medicine, 383(8), 743-753. https://doi.org/10.1056/NEJMoa1916525
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., Wehren, L. E., Lombardi, A., Santora, A. C., & Cummings, S. R. (2006). Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA, 296(24), 2927-2938. https://doi.org/10.1001/jama.296.24.2927
How this NU553 Unit 5 example is structured
Where a typical reflection follows the clock, this one follows the evidence, grouping what was said by source rather than by speaker. That choice keeps the account honest about why the author's view moved: not because the room disagreed, but because two documents did. The case for continuing gets one undiminished paragraph, including the reasonable point that bone density had not risen much. Each counterargument is then paired with its source and year, and the rarer harms that grow with duration, atypical femoral fracture and osteonecrosis of the jaw, are described with their low absolute rates so the reflection does not swing into alarm. The revised position is conditional. It names the reassessment during the pause, bone density at two years and a check for new fractures, and it records one thing the session left unsettled.
Get an NU553 Unit 5 example written to your instructions
For the Unit 5 seminar in NU553, the useful inputs are the therapy the group debated ending, the position you argued and the rubric. The sample reflection comes back within 24-48h, unbilled as a first request, grouped by evidence rather than by speaker, and closes on the conditions that would reverse its conclusion. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU553 Unit 5 questions, answered
Is it a weakness to admit losing the argument in a reflection?
Usually the opposite. Reflection rubrics tend to reward a visible change in reasoning, and conceding a point to better evidence is the clearest version of that. What matters is showing the original view fairly, naming the evidence responsible for the shift, and stating what would reverse it. A reflection that claims to have been right throughout gives a grader little to assess.
Should the reflection include bone density numbers?
Where the case supplies them, yes, bracketed as composite values and interpreted rather than listed. The femoral neck T-score matters here because the task force uses it to separate lower-risk patients from those who may benefit from continuing. Numbers without that interpretation add length without adding reasoning, which graders notice.
What if the seminar ended without agreement?
Then the reflection says so and explains where the disagreement sat: in the evidence, in how risk was weighed, or in the patient's preferences. An honest account of an unresolved question, with the author's current leaning and the fact that would settle it, usually scores better than a tidy consensus nobody actually reached.